The US Food and Drug Administration plans to add two more product areas to its ongoing Total Product Life Cycle Advisory Program (TAP), the agency announced on 1 July.
The expansion will add devices reviewed by the Office of Radiological Health and the Division of Ophthalmic Devices in fall 2024, to be followed by the Office of Orthopedic Devices...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?